{
    "clinical_study": {
        "@rank": "141075", 
        "arm_group": {
            "arm_group_label": "Omalizumab", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate for changes in the proteins produced in white blood\n      cells (basophils) in patients with chronic hives who are treated with and respond to\n      omalizumab."
        }, 
        "brief_title": "Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Urticaria", 
        "condition_browse": {
            "mesh_term": "Urticaria"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic urticaria (hives) for more than 6 weeks.\n\n          -  No improvement with standard doses of antihistamines (loratadine 10 mg daily,\n             desloratadine 5 mg daily, fexofenadine 180 mg daily, cetirizine 10 mg daily, or\n             levocetirizine 5 mg daily)\n\n        Exclusion Criteria:\n\n          -  Taken any oral steroids for 1 month prior to beginning the study.\n\n          -  Taken any other immunomodulatory drugs (sulfasalazine, hydroxychloroquine,\n             cyclosporine, methotrexate) for 1 month prior to beginning the study.\n\n          -  Physical urticaria as a primary diagnosis.\n\n          -  Known allergic precipitant of urticaria such as foods.\n\n          -  Urticarial Vasculitis.\n\n          -  Anemia.\n\n          -  Asthma.\n\n          -  Serum IgE>700 IU/ml.\n\n          -  Women of childbearing potential not using contraception method(s), as well as women\n             who are pregnant and/or breastfeeding.\n\n          -  Known sensitivity to omalizumab or this class of drug.\n\n          -  Use of any other investigational agent in the last 1 month.\n\n          -  Untreated intercurrent illness."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01701583", 
            "org_study_id": "12-0780"
        }, 
        "intervention": {
            "arm_group_label": "Omalizumab", 
            "intervention_name": "Omalizumab", 
            "intervention_type": "Drug", 
            "other_name": "Xolair"
        }, 
        "intervention_browse": {
            "mesh_term": "Omalizumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Idiopathic Urticaria", 
            "CIU", 
            "Urticaria", 
            "Chronic Hives", 
            "Xolair"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Denver", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80045"
                }, 
                "name": "University of Colorado Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Stephen Dreskin, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jenny Stitt, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria", 
        "overall_contact": {
            "email": "jenny.stitt@ucdenver.edu", 
            "last_name": "Jenny Stitt, M.D.", 
            "phone": "303-724-7205"
        }, 
        "overall_contact_backup": {
            "email": "Stephen.dreskin@ucdenver.edu", 
            "last_name": "Stephen Dreskin, M.D., Ph.D.", 
            "phone": "303-724-7190"
        }, 
        "overall_official": {
            "affiliation": "University of Colorado, Denver", 
            "last_name": "Stephen Dreskin, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In patients with chronic urticaria who respond clinically to omalizumab, the proteome of blood basophils will be measured at baseline (pre-treatment) and at weeks 6 and 13 (post-treatment).", 
            "measure": "Change in the basophil proteome", 
            "safety_issue": "No", 
            "time_frame": "Baseline through week 13"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01701583"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in basophil proteome in responders to omalizumab compared to non-responders to omalizumab", 
            "safety_issue": "No", 
            "time_frame": "Baseline through week 13"
        }, 
        "source": "University of Colorado, Denver", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Colorado, Denver", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}